Gamma Pharmaceuticals Expands Retail Reach in Pennsylvania
Published: Jun 09, 2009
LAS VEGAS, NV--(Marketwire - June 09, 2009) -
Gamma Pharmaceuticals Inc.
This represents another significant expansion of market share for Gamma whose brands are cited by consumers as being equal to or better than similar offerings from Pfizer Inc., Johnson & Johnson and Bayer. Gamma's CEO, Peter Cunningham, commented, "We are pleased to receive this order and look forward to a very strong brand building program with CoGo's in the territory. Retail chains are very supportive of Gamma's aggressive promotion programs and are taking product immediately."
Gamma Pharmaceuticals Inc. (www.gammapharma.com) is a marketing and product formulation company. The Company creates, registers and brands innovative product lines, including Nutritional Supplements, Personal Care Products and Over-The-Counter (OTC) pharmaceuticals. At present, Gamma manufactures in North America, and distributes in the United States and China. Gamma's products utilize a proprietary "Gel Delivery Technology®," offering one of the most innovative gel product forms; offering consumers a more pleasant experience with product forms that absorb more rapidly, are more convenient and taste great. Market categories Gamma targets are growing as rapidly as 60% per year.
Gamma master brands include: Brilliant Choice®, a range of children's vitamins, nutritional supplements and immune boosters, and Savvy®, a range of adult vitamins, nutritional supplements and immune boosters. Youth targeted products are sold as Jugular® Energy - "Go for the Jugular"™; and iceDROP Instant Hand Sanitizer™ (Beijing); In addition, Gamma has developed formulas and strategies for Metabolic Syndrome and Diabetes Type II, Stress reduction, Cognition, Well being, Menopause Symptoms, and Personal Care Products. Gamma also develops and manufactures house brands for major retailers. At this time, Gamma holds licenses for 9 SKUs in China.
Forward-Looking Statements: This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks and uncertainties, and actual circumstances, events or results may differ materially from those projected in such forward-looking statements. The Company cautions readers not to place undue reliance on any forward-looking statements. The Company does not undertake, and specifically disclaims any obligation, to update or revise such statements to reflect new circumstances or unanticipated events as they occur.
Gamma Pharmaceuticals Inc.
702 989 5262
651 204 2048